Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 359-364

  Okamoto, Teppei ^a   Yoneyama, Mihoko Sutoh ^a,c   Hatakeyama, Shingo ^b   Mori, Kazuyuki ^a   Yamamoto, Hayato ^a   Koie, Takuya ^a   Saitoh, Hisao ^c   Yamaya, Kanemitsu ^c   Funyu, Tomihisa ^c   Fukuda, Minoru ^d   Ohyama, Chikara ^a,b   Tsuboi, Shigeru ^a,b,c  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Oyokyo Kidney Research Institute   (Japan)

^d BURNHAM INSTITUTE   (United States)

Author keywords

Core2 O glycans; Metastasis; MUC1; NK cell immunity; Prostate cancer

Indexed keywords

CORE2 BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; CORE2 O GLYCAN; GLYCAN; GLYCOSYLTRANSFERASE; GRANZYME B; MUCIN 1; N ACETYLGLUCOSAMINYLTRANSFERASE; POLY N ACETYLLACTOSAMINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; ATTENUATION; CANCER CELL; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL INTERACTION; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME RELEASE; GLYCOSYLATION; HUMAN; HUMAN CELL; MALE; METASTASIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TUMOR ESCAPE;

CELL LINE, TUMOR; CELL SURVIVAL; GLYCOSYLATION; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; MALE; MUCIN-1; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84873845603     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1189     Document Type: Article

References (17)

1. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
2. Fuster MM and Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542, 2005.
3. Yousefi S, Higgins E, Daoling Z, Pollex-Krüger A, Hindsgaul O and Dennis JW: Increased UDP-GlcNAc: Gal beta 1-3GaLNAc-R (GlcNAc to GaLNAc) beta-1, 6-N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. J Biol Chem 266: 1772-1782, 1991.
4. Shimodaira K, Nakayama J, Nakamura N, Hasebe O, Katsuyama T and Fukuda M: Carcinoma-associated expression of core 2 beta-1, 6-N- acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression. Cancer Res 57: 5201-5206, 1997.
5. Machida E, Nakayama J, Amano J and Fukuda M: Clinicopathological significance of core 2 beta1, 6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization. Cancer Res 61: 2226-2231, 2001.
6. Hagisawa S, Ohyama C, Takahashi T, et al: Expression of core 2 beta1, 6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology 15: 1016-1024, 2005.
7. Tsuboi S, Sutoh M, Hatakeyama S, et al: A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J 30: 3173-3185, 2011.
8. Maemura K and Fukuda M: Poly-N-acetyllactosaminyl O-glycans attached to leukosialin. The presence of sialyl Le(x) structures in O-glycans. J Biol Chem 267: 24379-24386, 1992.
9. Tsuboi S, Hatakeyama S, Ohyama C and Fukuda M: Two opposing roles of O-glycans in tumor metastasis. Trends Mol Med 18: 224-232, 2012.
10. Suzuki Y, Sutoh M, Hatakeyama S, et al: MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis. Int J Oncol 40: 1831-1838, 2012.
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
12. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, et al: Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151: 767-776, 1993.
13. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
14. Hollingsworth MA and Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4: 45-60, 2004.
15. Lanier LL: Up on the tightrope: natural killer cell activation and inhibition. Nature Immunology 9: 495-502, 2008.
16. Cretney E, Shanker A, Yagita H, Smyth MJ and Sayers TJ: TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 84: 87-98, 2006.
17. Wagner KW, Punnoose EA, Januario T, et al: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13: 1070-1077, 2007.